TILT BIOTHERAPEUTICS
TILT Biotherapeutics is the leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. TILT is a preclinical stage company working in the field of cancer immunotherapy and will soon translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR-T therapy of solid tumors as currently achieved for CD19+ hematological tumors.
TILT BIOTHERAPEUTICS
Industry:
Apps Biotechnology Health Care
Founded:
2013-01-01
Address:
Helsinki, Southern Finland, Finland
Country:
Finland
Website Url:
http://www.tiltbio.com
Total Employee:
1+
Status:
Active
Total Funding:
48.08 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Font API Google Maps LetsEncrypt SSL By Default Organization Schema
Similar Organizations
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Advisors List
Board_member
2014-01-01
Board_member
Board_member
Current Employees Featured
Akseli Hemminki Founder & CEO @ TILT Biotherapeutics
Founder & CEO
2013-04-01
Founder
Investors List
U.S. Department of Defense
U.S. Department of Defense investment in Grant - TILT Biotherapeutics
European Innovation Council
European Innovation Council investment in Grant - TILT Biotherapeutics
European Innovation Council
European Innovation Council investment in Venture Round - TILT Biotherapeutics
ACME Investments
ACME Investments investment in Venture Round - TILT Biotherapeutics
Stephen Industries
Stephen Industries investment in Venture Round - TILT Biotherapeutics
Lifeline Ventures
Lifeline Ventures investment in Venture Round - TILT Biotherapeutics
Tesi
Tesi investment in Venture Round - TILT Biotherapeutics
European Innovation Council
European Innovation Council investment in Grant - TILT Biotherapeutics
Business Finland
Business Finland investment in Grant - TILT Biotherapeutics
Business Finland
Business Finland investment in Venture Round - TILT Biotherapeutics
Official Site Inspections
http://www.tiltbio.com Semrush global rank: 6.08 M Semrush visits lastest month: 1.13 K
- Host name: web34.zoner.fi
- IP address: 5.44.244.44
- Location: Finland
- Latitude: 60.1717
- Longitude: 24.9349
- Timezone: Europe/Helsinki
More informations about "TILT Biotherapeutics"
Our Team - TILT Biotherapeutics
TILT Biotherapeutics Oy Tukholmankatu 8 B, Biomedicum 2B, (2nd floor) 00290 Helsinki, Finland. TILT Biotherapeutics LLC One Broadway, 14th floor, MA 02142 Cambridge, USA.See details»
About TILT - TILT Biotherapeutics
Partnered clinical programs. The Company’s pioneering approach has been recognized by industry leaders. It has two collaborations with MSD, a tradename of Merck & Co., Inc., investigating TILT-123 in combination with KEYTRUDA® …See details»
TILT Biotherapeutics - Crunchbase Company Profile
TILT Biotherapeutics is the leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. TILT is a preclinical stage company working in the field of cancer immunotherapy and will soon translate …See details»
TILT Biotherapeutics Company Profile | Management and
Www.tiltbio.com TILT Biotherapeutics Profile and History TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic …See details»
TILT Biotherapeutics Ltd Company Overview, Contact Details ...
Feb 14, 2024 For contact: BD (at) tiltbio.com. Sign up for free to view info. Email Format Employee directory . Company Overview. Headquarters Tukholmankatu 8B c/o Biomedicum …See details»
TILT Biotherapeutics Oy - Drug pipelines, Patents, Clinical trials ...
Media contacts TILT Biotherapeutics COO Aino Kalervo aino@tiltbio.com Scius Communications Katja Stout +447789435990 katja@sciuscommunications.com Daniel Gooch +447747875479 …See details»
TILT Biotherapeutics Ltd Information - RocketReach
The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2). Multiple Phase I clinical trials are ongoing. For contact: BD …See details»
Tilt Biotherapeutics - Craft
Tilt Biotherapeutics has 5 employees at their 1 location and $15.7 m in total funding,. See insights on Tilt Biotherapeutics including office locations, competitors, revenue, financials, executives, …See details»
Contact - TILT Biotherapeutics
If you are interested in discussing partnering opportunities with TILT then please contact: bd@tiltbio.com Our Europe office is located at the Biomedicum research centre which is in …See details»
TILT Biotherapeutics - PitchBook
TILT Biotherapeutics General Information Description. Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment …See details»
TILT Biotherapeutics OY - European Commission
TILT Biotherapeutics is a clinical-stage biotechnology company developing novel gene therapies for cancer. The Company’s patented technology is about oncolytic immunotherapies that …See details»
TILT Biotherapeutics - Overview, News & Similar companies
Jun 14, 2022 TILT Biotherapeutics contact info: Phone number: +358 919125464 Website: www.tiltbio.com What does TILT Biotherapeutics do? TILT Biotherapeutics is a clinical-stage …See details»
TILT Biotherapeutics Provides Update on International Clinical Trial ...
Dec 5, 2024 Data Presented at ESMO-IO supports the potential of personalized treatment strategies to improve clinical trial outcomesHELSINKI, Finland, Dec. 05, 2024 (GLOBE …See details»
TILT Biotherapeutics Provides Update on International Clinical Trial ...
Dec 5, 2024 Data Presented at ESMO-IO supports the potential of personalized treatment strategies to improve clinical trial outcomes. HELSINKI, Finland, Dec. 05, 2024 (GLOBE …See details»
Science - TILT Biotherapeutics
TILT was founded on the unique discovery that oncolytic adenoviruses potently stimulate T-cell responses in humans. Our lead programme was designed by leveraging insights gained by …See details»
TILT Biotherapeutics Presents Clinical Data on TILT-123 in …
Apr 10, 2024 Results Reveal Mechanism of Action and Correlative Analyses DataHELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage …See details»
TILT Biotherapeutics Announces over $10 Million Financing to …
Jun 14, 2022 Media contacts TILT Biotherapeutics CBO Aino Kalervo aino@tiltbio.com. Scius Communications Katja Stout +447789435990 katja@sciuscommunications.com. Social Media …See details»
Partners - TILT Biotherapeutics
Bd@tiltbio.com. TILT Biotherapeutics Oy Tukholmankatu 8 B, Biomedicum 2B, (2nd floor) 00290 Helsinki, Finland. TILT Biotherapeutics LLC One Broadway, 14th floor, MA 02142 Cambridge, …See details»
TILT Biotherapeutics Secures Over EUR 6 million to Advance …
Jun 16, 2020 TILT Biotherapeutics CBO Aino Kalervo aino@tiltbio.com. Scius Communications Katja Stout +447789435990 katja@sciuscommunications.com. Release Summary. TILT …See details»